How does LDBB's PE Ratio compare to its peers?

LDBB is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (22.5x).

How does LDBB's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

LDBB is good value based on its Price-To-Earnings Ratio (16.5x) compared to the European Pharmaceuticals industry average (20.7x).

What is LDBB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LDBB is expensive based on its Price-To-Earnings Ratio (16.5x) compared to the estimated Fair Price-To-Earnings Ratio (16.4x).

What is the Fair Price of LDBB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

LDBB (€4.73) is trading below our estimate of [[fair value]] (€17.44)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

H. Lundbeck (DB:LDBB) - Stock Price, News & Analysis

LDBB Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

LDBB fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	3/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 72.9% below our estimate of its fair value

Earnings are forecast to grow 8.57% per year

Earnings have grown 7% per year over the past 5 years

Risk Analysis

No risks detected for LDBB from our risk checks.

H. Lundbeck A/S Competitors

Dermapharm Holding

XTRA:DMP

€1.9b

Merck KGaA

XTRA:MRK

€62.3b

PharmaSGP Holding

XTRA:PSG

€297.4m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	DKK 4.73
52 Week High	DKK 5.54
52 Week Low	DKK 3.67
Beta	0.18
11 Month Change	-7.71%
3 Month Change	-7.53%
1 Year Change	15.87%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	9.51%

Recent updates

Shareholder Returns

	LDBB	DE Pharmaceuticals	DE Market
7D	1.1%	-7.5%	-0.5%
1Y	15.9%	-24.1%	8.3%

Return vs Industry: LDBB exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.

Return vs Market: LDBB exceeded the German Market which returned 8.3% over the past year.

Price Volatility

Is LDBB's price volatile compared to industry and market?
LDBB volatility
LDBB Average Weekly Movement	4.4%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: LDBB has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: LDBB's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1951	5,800	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
LDBB fundamental statistics
Market cap	€5.72b
Earnings (TTM)	€360.22m
Revenue (TTM)	€2.87b

16.5x

P/E Ratio

2.1x

P/S Ratio

Is LDBB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LDBB income statement (TTM)
Revenue	DKK 21.44b
Cost of Revenue	DKK 4.37b
Gross Profit	DKK 17.07b
Other Expenses	DKK 14.39b
Earnings	DKK 2.69b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)	2.71
Gross Margin	79.63%
Net Profit Margin	12.53%
Debt/Equity Ratio	15.6%

How did LDBB perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

26%

Payout Ratio

LDBB Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

XTRA:DMP

€1.9b

XTRA:MRK

€62.3b

XTRA:PSG

€297.4m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

First quarter 2023 earnings released: EPS: kr.0.89 (vs kr.0.41 in 1Q 2022)

Full year 2022 earnings released

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

Less than half of directors are independent

Third quarter 2022 earnings released

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

Second quarter 2022 earnings released: EPS: kr.0.51 (vs kr.1.90 in 2Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

H. Lundbeck A/S Fundamentals Summary

16.5x

2.1x

Earnings & Revenue

Dividends